
Oncology NEWS International
- Oncology NEWS International Vol 11 No 12
 - Volume 11
 - Issue 12
 
10 Centers Share First Avon ‘Progress for Patients’ Grants
BETHESDA, Maryland-Six initial breast cancer research grants totaling $2.5 million have been awarded through the National Cancer Institute-Avon Foundation’s Progress for Patients program to fund innovative translational science at 10 research institutions. The program administers a $20 million pledge from the Avon Foundation. The initial grants consist of $1.99 million from the Avon Foundation and $660,000 from NCI.
BETHESDA, MarylandSix initial breast cancer research grants totaling $2.5 million have been awarded through the National Cancer Institute-Avon Foundation’s Progress for Patients program to fund innovative translational science at 10 research institutions. The program administers a $20 million pledge from the Avon Foundation. The initial grants consist of $1.99 million from the Avon Foundation and $660,000 from NCI.
Lead institutions for the six grants are the University of Alabama, Baylor College of Medicine, Fred Hutchinson Cancer Center, University of North Carolina at Chapel Hill, Duke University, and Dana Farber-Harvard Cancer Institute.
Articles in this issue
almost 23 years ago
Stereotactic Radiosurgery Benefits Brain Met Patientsalmost 23 years ago
Cancer Risk From Tainted Polio Vaccine Undetermined: IOM Reportalmost 23 years ago
Tailored Messages Motivate Women to Get Mammogramsalmost 23 years ago
Chemo/Rituximab Is Effective as First-Line CLL Therapyalmost 23 years ago
Preoperative Capecitabine/RT Downstages Rectal Canceralmost 23 years ago
Intraoperative Lymphatic Mapping Enhances Cancer Stagingalmost 23 years ago
Rituximab Ups Survival in Aggressive and Indolent NHLalmost 23 years ago
Genzyme Molecular Oncology Begins Kidney Cancer Vaccine Trialalmost 23 years ago
Lower Breast Cancer Survival in Hispanics: New Mexico StudyNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































